Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by Galaxym31on Jun 12, 2024 10:43pm

208 Views

Post# 36086331

Why does TLT need 450 day response when

10.3 months

Patients receiving Keytruda lived for 10.3 months (median overall survival) compared to 7.4 months with chemotherapy. An equal number of patients (81%) in both the Keytruda and chemotherapy groups had their cancer spread, grow, or get worse. Expected income this year for Merck is 17 billion US $ . The patent expires in 2028 .

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1